Intrahepatic Cholangiocarcinoma: Epidemiological Trends, Risk Factors, Diagnostic Challenges, and Advances in Personalized Therapy — A Comprehensive Review.
New precision drugs targeting specific mutations and immune combinations are improving outcomes for a rare liver cancer historically difficult to treat.
This comprehensive review covers the rising global burden of intrahepatic cholangiocarcinoma, highlighting its diagnostic challenges (often late-stage at presentation) and reviewing advances in targeted therapy (FGFR2/IDH1/NTRK inhibitors) and immunotherapy combinations. The review is timely given recent regulatory approvals and ongoing combination trials in this rare cancer with high unmet need.
What the study was
- Study design
- Comprehensive narrative review
- Population
- Intrahepatic cholangiocarcinoma (iCCA) patients globally
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal of Gastroenterology and Hepatology
Why it surfaced
iCCA is a rare biliary malignancy with late diagnosis and limited treatment options; review consolidates current personalized therapy landscape post-FGFR2/IDH1 approvals; practical reference for rare disease surveillance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.